Amber Salzman

The Stop ALD Foundation is a non-profit organization based in Houston that focuses on accelerating the process of developing new knowledge and new therapies for adrenoleukodystrophy (ALD). ALD is a deadly genetic disease that affects 1 in 18,000 people, most severely affecting boys and men. This brain disorder destroys myelin, the protective sheath that surrounds the brain's neurons, and it knows no racial, ethnic, or geographic barriers. The foundation's mission is to develop therapies for ALD and raise awareness about the disease.

Ald Connect, Inc. is a non-profit organization that aims to improve health outcomes for patients with adrenoleukodystrophy (ALD) by empowering patients, raising awareness, and accelerating the translation of scientific advances into better clinical care. The non-profit company is based in Middleton, MA, USA. ALD is a rare genetic disease that affects the adrenal glands, the spinal cord, and the white matter of the nervous system. Ald Connect offers various opportunities to get involved with their community, including advocacy, fundraising, volunteering, and participating in their programs or events.

Ohana Biosciences, Inc. operates early stage biotechnology firm. The company is headquartered in Cambridge, MA.

Lankenau Institute for Medical Research operates as a non-profit biomedical research centre. It provides human health and well being through technology development and the training to the next generation of scientists and physicians. The company was founded in 1917 and is headquartered Wynnewood, PA.

AviadoBio Ltd. is a gene therapy company based in London, UK. AviadoBio's technology is based on pioneering research from King's College London and the UK Dementia Research Institute. The British company's mission is to develop and deliver transformative gene therapies for neurodegenerative disorders, including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The company is developing AVB-101 for patients with FTD-GRN. AviadoBio's investors include New Enterprise Associates (NEA), Monograph Capital, Advent Life Sciences, EQT Lifesciences, Dementia Discovery Fund (DDF), F-Prime Capital, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), and LifeArc. The company was founded by Youn Bok Lee, Do Young Lee, Chris E. Shaw, and Lisa Deschamps has been the CEO of the company since 2021.

Epicrispr Biotechnologies, Inc. is a leading epigenetic editing company based in South San Francisco, CA. The company leverages the power of CRISPR without cutting DNA through its proprietary Gene Expression Modulation System (GEMS), which includes the smallest Cas protein known to work in human cells. Epic's lead program is in IND-enabling studies for the treatment of facioscapulohumeral muscular dystrophy (FSHD), and additional programs seek to address alpha-1 antitrypsin deficiency (A1AD), heterozygous familial hypercholesterolemia (HeFH), and other indications. The company is financially backed by Horizons Ventures and other leading investors. The company was founded by Lei Stanley Qi, and the CEO is Amber Salzman.